Related Experiment Videos
Statistical aspects of early termination in the beta-blocker heart attack trial
Insights
The Beta-Blocker Heart Attack Trial found that propranolol significantly reduced mortality by 26% in patients after a heart attack. This led to the early termination of the trial due to overwhelming evidence of benefit.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Recent myocardial infarction poses a significant risk of mortality.
- Beta-blockers are a class of drugs used to manage cardiovascular conditions.
- The Beta-Blocker Heart Attack Trial (BHAT) investigated the efficacy of propranolol post-myocardial infarction.
Purpose of the Study:
- To evaluate the effectiveness of propranolol in reducing mortality following a recent myocardial infarction.
- To compare the outcomes of patients treated with propranolol versus placebo.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 3837 patients.
- Patients with a recent myocardial infarction were assigned to receive either propranolol or a placebo.
- Statistical methods were employed to assess mortality trends and significance, accounting for early termination.
Main Results:
- The propranolol group demonstrated a statistically significant 26% lower mortality rate compared to the placebo group.
- The trial was terminated 9 months early based on the recommendation of the Policy and Data Monitoring Board.
- Results were consistent across various subgroups, clinical centers, and causes of death, with complete follow-up.
Conclusions:
- Propranolol significantly reduces mortality in patients following a myocardial infarction.
- The compelling evidence of benefit supported the early discontinuation of the trial.
- These findings underscore the importance of beta-blocker therapy in post-myocardial infarction care.
Abstract:
The Beta-Blocker Heart Attack Trial was a randomized double blind controlled trial comparing propranolol with placebo in 3837 patients with a recent myocardial infarction. The trial was terminated on recommendation of the Policy and Data Monitoring Board 9 months before the scheduled closing date. The propranolol group, at the time of the decision, had a 26% lower mortality (z = 2.82). Many issues were considered in this decision. These included the magnitude of the overall results; consistency of results across subgroups, clinical centers, and cause of death; and completeness of follow-up. Two basic statistical methods were used in declaring the overall mortality results significant. The first method evaluated the current survival data taking into account the issue of repeated significance testing. The second method evaluated whether the observed trend was so impressive that the conclusion was unlikely to change even if the trial should continue to the scheduled end. These two methods, as well as other considerations led to the recommendation to discontinue the trial.